The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

The main purpose of this research is to determine if the combination of these three medications can help patients live longer compared to using docetaxel by itself. The study involves two groups of patients – one receiving all three medications, while the other group receives only docetaxel. The medications are given through different methods: tislelizumab and docetaxel are given through an intravenous infusion (into a vein), while N-803 is given as a subcutaneous injection (under the skin).

During the study, patients will receive treatment and have regular check-ups to monitor their health and how well the treatment is working. The treatment will continue as long as it appears to be helping and the side effects are manageable. Doctors will use special scanning techniques to measure if the tumors are shrinking and will track how long patients live after starting the treatment.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of the study is to compare how well the combination of zanzalintinib and pembrolizumab works against using pembrolizumab alone in treating this type of cancer. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. Some participants may receive a placebo, which looks like the real medication but does not contain the active drug. The study will involve regular check-ups and monitoring to assess the treatment’s effects and any side effects experienced by the participants.

The study will take place over several months, with participants receiving treatment and being monitored for changes in their condition. The goal is to determine if the combination of zanzalintinib and pembrolizumab can improve outcomes for patients with this type of cancer. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to gather important data on the treatment’s effectiveness.

The purpose of this study is to determine if the combination of ceralasertib and durvalumab is more effective than docetaxel in treating patients with this type of lung cancer. Participants in the study will be randomly assigned to receive either the combination therapy or docetaxel. The study will monitor the overall survival of participants, which refers to the length of time patients live after starting the treatment. Other aspects being evaluated include how long the cancer stays under control, the quality of life reported by participants, and the safety and tolerability of the treatments.

The study will take place over a period of time, with participants receiving treatment for up to 24 months. During this time, participants will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for patients with advanced or metastatic non-small cell lung cancer.

The purpose of the study is to compare how the body absorbs and processes these two forms of pembrolizumab in patients who are receiving it as their first treatment for this type of lung cancer. Participants will receive either the subcutaneous or intravenous form of pembrolizumab, and the study will monitor how the drug behaves in the body over time. This includes looking at how much of the drug is present in the blood at different times and how long it stays in the body.

Throughout the study, researchers will also observe the overall health and quality of life of the participants, as well as any side effects they may experience. The study aims to provide valuable information on the safety and effectiveness of these two methods of administering pembrolizumab, which could help improve treatment options for patients with this type of lung cancer.

The purpose of this study is to compare how well MK-1084 combined with MK-3475A works compared to MK-3475A combined with chemotherapy in treating this type of lung cancer, particularly in people whose tumors show a certain marker called PD-L1. The study will look at how long participants live without their cancer getting worse, how long they live overall, whether their tumors shrink or disappear, and how long any response to treatment lasts. The study will also monitor what side effects occur and whether participants need to stop treatment because of these side effects.

During the study, participants will receive one of the two treatment combinations. They will have regular check-ups where doctors will examine them, take blood samples, and perform scans to see how the cancer is responding to treatment. Participants will also be asked to complete questionnaires about their quality of life, including questions about breathing difficulties, coughing, and chest pain. The doctors will track any health problems that occur during treatment and measure changes in symptoms and overall well-being throughout the study.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The study involves patients whose lung cancer has already been treated with platinum-based chemotherapy combined with immunotherapy but has since returned. Both medications in this study will be given through intravenous infusion (delivered directly into a vein). GSK5764227 will be given at doses up to 8 milligrams per kilogram of body weight, while topotecan will be given at doses up to 1.5 milligrams per square meter of body surface area.

This is an open-label study, which means both the doctors and patients will know which treatment is being given. The treatment period may last up to 24 months, during which time doctors will monitor how well the cancer responds to the treatment and track the overall survival of patients. Throughout the study, patients will have regular check-ups to monitor their health and assess how well the treatment is working.

The purpose of this research is to determine if using THIO followed by cemiplimab helps patients with advanced NSCLC live longer compared to using standard chemotherapy alone. Both treatments are given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either the THIO/cemiplimab combination or one of the standard chemotherapy medications. The treatment period may continue for up to 24 months. Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will also watch for any side effects that may occur during the treatment period.

Participants may receive a combination of the study drug pumitamig (also referred to as BNT327) and chemotherapy. The chemotherapy medications involved include oxaliplatin, fluorouracil, and capecitabine, sometimes used alongside calcium folinate. In the first part of the study, two different doses of pumitamig are tested to see which one works best. In the second part, the more effective dose is compared to a standard treatment consisting of nivolumab and chemotherapy.

The study is conducted in stages. Initially, the goal is to determine which dose of the new medicine is most effective at controlling tumor growth while minimizing side effects. Following this, the selected dose is evaluated to see if it can extend progression-free survival, which is the length of time a patient lives with the disease without it getting worse, and overall survival, which is the total length of time a patient remains alive.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

The purpose of the study is to evaluate how well these new combinations of immune system treatments work compared to dostarlimab alone in people with this type of cancer that shows the PD-L1 marker. The main measure of success will be looking at how many people experience either complete disappearance of their tumors or significant shrinking of their tumors during treatment. Participants will be assigned randomly to receive one of the treatment combinations, and the study will follow them for up to 24 months to track how their cancer responds.

During the study, participants will receive their assigned treatment through infusions into a vein, and doctors will regularly check how the tumors are responding using imaging scans and physical examinations. Tissue samples from the tumor will be needed to confirm that the cancer meets the study requirements and to check for the PD-L1 marker. The study is designed as an open-label trial, which means both the participants and their doctors will know which treatment is being given. This is a platform study using a master protocol, which means it is set up in a way that allows testing of multiple treatment combinations at the same time.

The purpose of the study is to find the best dose of izalontamab brengitecan in the first part of the study and then to compare how well this new treatment works compared to platinum-based chemotherapy in preventing the cancer from getting worse. The study is divided into two phases. In the first phase, researchers will look at the safety and effectiveness of different doses of izalontamab brengitecan to determine the recommended dose for the second phase. In the second phase, patients will be randomly assigned to receive either izalontamab brengitecan at the recommended dose or platinum-based chemotherapy, and the study will measure how long patients live without their cancer getting worse.

During the study, patients will receive their assigned treatment through infusions into a vein, with some medications also given as injections under the skin. The treatments will be given in cycles over an extended period, and patients will be monitored regularly to check how the cancer responds to treatment and to watch for any side effects. The study will collect information about survival, how long the cancer stays under control, and the overall safety of the treatments being tested.

The purpose of the study is to find out if adding BMS-986504 to pembrolizumab and chemotherapy can help people with this type of lung cancer live longer without their cancer getting worse, and to see if it can help them live longer overall, compared to treatment with placebo plus pembrolizumab and chemotherapy. The study will also look at how well the cancer responds to treatment and how long any response lasts, as well as checking for any unwanted effects that the treatments may cause.

The study will be conducted in two phases. Participants will be randomly assigned to receive either BMS-986504 or placebo, both given together with pembrolizumab and chemotherapy. The specific chemotherapy medicines used will depend on the type of lung cancer each person has. Throughout the study, doctors will perform regular check-ups and scans to see how the cancer is responding to treatment and to monitor for any side effects. Treatment will continue for as long as it is helping and not causing unacceptable side effects.

The main purpose of this research is to determine if izalontamab brengitecan works better than standard chemotherapy treatments in patients who cannot receive certain types of immunotherapy treatments (anti-PD1/PD-L1). The study will measure how long patients live without their cancer getting worse and their overall survival time. During treatment, some patients may also receive pegfilgrastim, a supportive care medicine that helps the body make white blood cells.

The medications will be given in different ways – some through an intravenous infusion directly into a vein, while others, like capecitabine, are taken by mouth as tablets. The study will continue for several years to gather information about how well the treatments work and how safe they are for patients.

The treatment involves taking zipalertinib or placebo tablets by mouth, combined with chemotherapy medications given through an intravenous infusion. The chemotherapy drugs used in this study are cisplatin, carboplatin, and pemetrexed. These medications are commonly used to treat lung cancer after surgery to reduce the risk of cancer coming back.

During the study, participants will be randomly assigned to receive either zipalertinib tablets or matching placebo tablets. Neither the participants nor their doctors will know which treatment they are receiving. The treatment period may last up to 36 months, during which participants will receive regular medical check-ups to monitor their health and evaluate how well the treatment is working.

The treatment plan involves giving medications before surgery (neoadjuvant therapy) to shrink the tumor. The study medications are given through an intravenous infusion directly into the bloodstream. Some participants will receive the new combination with sacituzumab tirumotecan, while others will receive standard chemotherapy which may include doxorubicin, epirubicin, or cyclophosphamide. All participants will also receive dexamethasone to help manage side effects, and some may receive capecitabine as part of their treatment.

The main purpose of this research is to determine whether the new treatment combination is more effective at eliminating cancer cells before surgery compared to standard chemotherapy. The study will also track how long participants remain free of cancer after treatment and monitor their overall survival. Researchers will carefully watch for any side effects and evaluate how the treatments affect participants’ quality of life.

The main purpose of this research is to understand how the body processes nivolumab when it is given under the skin in two different doses, along with ipilimumab and chemotherapy. The study will look at how the medications work together and how they are processed by the body.

During the study, participants will receive nivolumab as an injection under the skin, while ipilimumab and chemotherapy medications will be given through a vein. The treatment will continue for up to 24 months. Throughout the study, doctors will monitor how participants respond to the treatment and check for any side effects that may occur.

The main purpose of this research is to evaluate how well different doses of BMS-986504 work in treating this specific type of lung cancer. The medication will be given to patients whose cancer has continued to grow or spread despite previous treatments. This is an open-label study, which means both doctors and patients will know which treatment is being given.

During the study, patients will take the medication and have their cancer monitored regularly to see how it responds to the treatment. Doctors will track if the tumors shrink, stay the same size, or grow. They will also monitor how patients feel and any side effects they may experience. The study will look at various aspects of the treatment’s effectiveness, including how long the cancer stays controlled and how long patients survive after starting the treatment.

The study involves people whose tumors test negative for a protein called HER2 but positive for two other proteins called CLDN18.2 and PD-L1. During the study, participants will receive either zolbetuximab or a placebo along with pembrolizumab and chemotherapy through intravenous infusions. Some chemotherapy medications will be given as tablets to take by mouth.

Researchers will track how long participants live, whether their cancer grows or spreads, and how their tumors respond to treatment. They will also monitor participants for any side effects from the treatment combination. The study will check blood samples to measure drug levels and test for the body’s immune response to the medications.

The study will compare two different treatment approaches: one group will receive MK-1084, cetuximab, and mFOLFOX6, while the other group will receive mFOLFOX6 either alone or with another drug called bevacizumab. The main purpose is to determine if adding MK-1084 and cetuximab to standard chemotherapy is safe and effective for treating this specific type of colorectal cancer.

During the study, patients will receive their assigned treatments through a combination of oral tablets (MK-1084) and intravenous infusions (other medications). The medications will be given according to a specific schedule, and patients will be monitored regularly to assess how well the treatment is working and to check for any side effects.

The purpose of this research is to determine how well sacituzumab tirumotecan works, both by itself and when combined with pembrolizumab, compared to standard treatments. The study will look at how these treatments affect cancer growth and patient survival. All medications will be given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either sacituzumab tirumotecan alone, sacituzumab tirumotecan with pembrolizumab, or one of the standard treatment options. The study will monitor how the cancer responds to treatment and track any side effects that may occur. Patients will also complete questionnaires about their quality of life during treatment.

The purpose of the study is to see if Ifinatamab deruxtecan can help people with advanced or metastatic ESCC live longer compared to the other chemotherapy treatments. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of up to 54 weeks, during which participants will be closely monitored by healthcare professionals. The study will also look at how the treatment affects the quality of life and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and imaging tests like computed tomography (CT) or magnetic resonance imaging (MRI) to track the progress of the disease. The study aims to provide valuable information on the effectiveness and safety of Ifinatamab deruxtecan for treating ESCC, potentially offering a new option for patients with this challenging condition.

The purpose of the study is to see if the combination of Sigvotatug vedotin and pembrolizumab is better at treating NSCLC compared to using pembrolizumab alone. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. The study will monitor how long patients live and how long they remain free from cancer progression. The trial will also look at the safety of the treatments and any side effects that may occur.

Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effectiveness of the treatment. The trial aims to provide valuable information that could improve treatment options for people with advanced non-small cell lung cancer.

The main goal of the study is to determine if the combination of nivolumab and relatlimab with chemotherapy is more effective in extending the lives of patients compared to pembrolizumab with chemotherapy. The study will also look at other factors, such as how long the cancer stays under control and the overall response to the treatments. Participants will be monitored for any side effects from the medications.

The study will take place over several years, with the estimated completion date in 2027. Participants will be randomly assigned to one of the two treatment groups and will receive their assigned treatment as part of the study. The results will help determine the best first-line treatment option for people with this type of lung cancer.

The treatment being tested includes a combination of Adagrasib, Pembrolizumab, and chemotherapy drugs such as Cisplatin, Pemetrexed, and Carboplatin. Pembrolizumab is a type of medication that helps the immune system fight cancer, while chemotherapy uses drugs to kill cancer cells. The study will compare this combination to a similar treatment that includes a placebo instead of Adagrasib. Another medication, Palonosetron, is used to help manage side effects like nausea during the treatment.

Participants in the study will receive these treatments through infusions, which means the medication is given directly into the bloodstream. The study will last for a period of time, and researchers will monitor the participants to see how well the cancer responds to the treatment and how long the patients live. The aim is to determine if the addition of Adagrasib can improve outcomes for patients with this specific type of lung cancer.

The purpose of the study is to see how well Sacituzumab Govitecan works compared to the usual treatments in improving the condition of patients with ES-SCLC. Participants in the study will receive either Sacituzumab Govitecan or the standard treatment, which may include other medications. The study will monitor how the cancer responds to the treatment and how long patients live after receiving the treatment. Some participants may receive a placebo as part of the study.

The study will take place over a period of time, with regular check-ups and assessments to track the progress of the treatment. Participants will receive their treatment through an intravenous method, which means the medication will be given directly into a vein. The study aims to provide valuable information on the effectiveness of Sacituzumab Govitecan in treating ES-SCLC and to explore its potential as a new treatment option for patients with this type of lung cancer.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of the study is to evaluate how well the new combination works as a first-line treatment for patients with this type of cancer. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure the results are unbiased. The study will take place over a period of time, with regular assessments to monitor the progress and health of the participants.

Throughout the study, researchers will focus on key outcomes such as progression-free survival, which measures how long patients live without the cancer getting worse, and overall survival, which measures how long patients live overall. The study will also look at the safety of the treatments and any side effects that may occur. By the end of the study, the goal is to determine if the new treatment combination offers a better option for patients with this type of cancer.

The purpose of this study is to evaluate the safety and effectiveness of the combination of ABBV-400 and Budigalimab in patients with advanced or metastatic non-squamous NSCLC. Participants in the study will receive these medications through an intravenous infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor participants for any side effects and changes in their cancer to determine the best dose for future studies.

Throughout the study, participants will be closely observed to assess how their cancer responds to the treatment. The study aims to find out if this combination can help control the disease and improve the quality of life for patients with this type of lung cancer. The trial will continue until the researchers gather enough information to understand the treatment’s impact on the disease.

The purpose of the study is to evaluate the effectiveness of these medications when used as a follow-up treatment, also known as consolidation therapy, to help prevent the cancer from returning or worsening. Participants in the study will receive either Toripalimab alone, a combination of Toripalimab and Tifcemalimab, or a placebo. The study is designed to compare the outcomes of these different treatment approaches.

During the study, participants will receive the medications through an intravenous (IV) infusion, which means the medicine is given directly into a vein. The study will monitor participants over a period of time to assess their overall survival and how long they remain free from cancer progression. The trial aims to provide valuable information on whether these treatments can improve outcomes for patients with LS-SCLC.

The purpose of the study is to see how well Elacestrant works compared to these standard treatments in preventing the return of breast cancer. Participants in the study will be randomly assigned to receive either Elacestrant or one of the standard hormone therapies. The study will last for a period of up to 60 months, during which participants will take their assigned medication daily. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition.

The study will also look at how the treatments affect the participants’ quality of life, including any side effects they may experience. This will help researchers understand the overall impact of Elacestrant compared to the standard treatments. The information gathered from this study will contribute to better understanding and potentially improving treatment options for people with this type of breast cancer.

The purpose of this study is to determine if the combination of BMS-986489 with chemotherapy is more effective than atezolizumab with chemotherapy in treating ES-SCLC. Participants will be randomly assigned to one of the two treatment groups. The study will monitor how long participants live after starting the treatment, as well as other factors like how long it takes for symptoms to worsen, the safety of the treatments, and how well the tumors respond to the treatments.

Throughout the study, participants will receive their treatments through an intravenous (IV) infusion, which means the medicine will be given directly into a vein. The study will continue until the estimated end date in 2031, with the goal of providing valuable information on the effectiveness and safety of these treatment combinations for people with ES-SCLC.

The purpose of the study is to evaluate how effective and safe ABP 206 is compared to OPDIVO® in patients who have not received any previous treatment for their advanced melanoma. Participants in the study will receive either ABP 206 or OPDIVO® for a period of up to 24 months. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments. The study will monitor the response to the treatment, including any changes in the size of the melanoma, and will also track any side effects or immune reactions that may occur.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their melanoma. The study aims to provide valuable information on the effectiveness of ABP 206 compared to OPDIVO® in treating unresectable or metastatic melanoma, potentially offering new insights into treatment options for this condition.

The main goal of the study is to evaluate how well the treatment works in stopping the cancer from getting worse. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over a period of time, and participants will be monitored regularly to assess their health and the progression of the cancer. The trial will also look at the safety of the treatment and any side effects that may occur.

Participants in the study will be adults with a specific type of gastric cancer that is HER2-negative and expresses a protein called Claudin 18.2. The study aims to provide valuable information on whether the addition of zolbetuximab to the standard chemotherapy regimen can improve outcomes for patients with this challenging form of cancer. The trial is expected to continue until 2025, with the hope of finding a more effective treatment option for those affected by this disease.